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Gproteinscomprise0.5%ofproteinsencoded
by mammalian genomes. To date, there exists
a lack of small-molecule modulators that could
contribute to their functional study. In this re-
port, we present the use of H-Ras to develop a
system that answers this need. Small molecules
that allow for the highly specific inhibition or ac-
tivation of the engineered G protein were devel-
oped. The rational design preserved binding of
the natural substrates to the G protein, and the
mutationswere functionally innocuous inacellu-
lar context. This tool can be used for isolating
specific G protein effectors, as we demonstrate
with the identification ofNol1 as aputative effec-
tor of H-Ras. Finally, the generalization of this
system was confirmed by applying it to Rap1B,
suggesting that this method will be applicable
to other G proteins.
INTRODUCTION
The human genome contains more than 160 G proteins
[1], encompassing small G proteins, translation-elonga-
tion factors, and the a subunits of heterotrimeric G pro-
teins. With the exception of elongation factors, they act
as precisely engineered molecular switches and are
deeply woven into the signal transduction network [2].
Small G proteins consist of an invariant core—the guanine
nucleotide-binding domain coupled to the switch I and II
areas regulating interactions with other macromole-
cules—and variable N and C termini additions specific to
each enzyme [2]. Binding of GTP or GDP locks G proteins
into dissimilar ‘‘on’’ and ‘‘off’’ conformations, respectively,
and thereby regulates their affinities to other proteins
(effectors) and initiates signaling cascades (Figure 1A).
Their cycling between GDP- or GTP-bound conformations
is controlled by GTPase-activating proteins (GAPs), GDP-
dissociation inhibitors (GDIs), and guanine nucleotide-
exchange factors (GEFs). These proteins determine the
amount of GTP-bound enzyme available to bind to effec-
tors and thus ultimately control the amplitude and duration
of the downstream signals (Figure 1A).
A wide variety of diseases have their roots in deregu-
lated G protein activities or have harmful signals conveyedChemistry & Biology 14, 1007–1018through them [3–5]. Despite their great potential as drug
targets, no active-site inhibitors are known to date. Tradi-
tionally, the high affinity of G proteins for their substrates
(KD of 10 pM) and the high intracellular concentration
of GTP (1 mM) have been blamed for this failure [6].
The lack of such tools to allow for specific and temporal
control over the activities of G proteins has prevented the
contribution of small molecules to the elucidation of their
pathways [7]. This is in sharp contrastwithkinases, in which
the availability of even partially selective inhibitors greatly
facilitated their functional study in cellular systems [8].
The convergent engineering of small-molecule/protein
interfaces to address biological questions has emerged
as a powerful new tool [9]. This strategy allows for tight
control over the biological activity of a desired protein by
combining the advantages of both chemistry and genet-
ics. Diverse systems have been studied by using this
orthogonal chemical-genetic methodology including 7-
transmembrane receptors [10], nuclear hormone recep-
tors [11], methyl transferases [12], chemical inducers of
dimerization [13], kinases [14, 15], and myosin [16].
G proteins themselves were the object of pioneering
chemical-genetic studies [17]. A change in substrate
specificity from GTP to XTP (xanthosine 50-triphosphate)
was achieved by mutating a conserved aspartate residue
(D119 in H-Ras) interacting with the exocyclic C(2) amine
of GTP to asparagine. The protein-nucleotide hydrogen
bond thus abolished could be reestablished if XTP was
used rather than GTP. This system was used to transform
several G proteins into XTPases and enabled their study in
in vitro systems [18]. However, XTP production occurs
spontaneously in cells and is postulated to be mutagenic,
as noncanonical nucleotides can be incorporated into
nucleic acids [19]. Accordingly, a cellular protection
mechanism that employs NTPases keeps XTP intracellu-
lar concentrations at a very low level, which is inadequate
for the proper function of the modified G proteins [20]. Due
to the low intracellular concentrations of XDP and XTP, the
mutant enzyme therefore still binds GDP and GTP in vivo.
Since the affinity of XTPases toward their natural sub-
strates GDP and GTP is decreased by three orders of
magnitude, the ‘‘on’’ and ‘‘off’’ switch mechanism is ren-
dered ineffective and is replaced by a binding equilibrium
[21]. As GTP is much more abundant than GDP, the major-
ity of the mutant enzyme is in the GTP-bound form, thus
making it constitutively active and rendering the applica-
tion of this approach to in vivo studies impractical [21].
As a result, the design of a mutant G protein retaining its, September 2007 ª2007 Elsevier Ltd All rights reserved 1007
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(A) Schematic representation of small G protein signaling. Upstream signals are conveyed to G proteins through GDI, GAP, and GEF proteins. The
conformational change due to GTP binding allows effectors to bind the G protein-GTP complex and conveys the signal downstream.
(B) Ribbon representation of H-Ras bound to GDP; amino acids L19 and N116 are highlighted along with the switch I and II regions.natural nucleotide selectivity but susceptible to specific
orthogonal small molecules is highly desirable [7].
We report, herein, the rational design and engineering of
a system that allows for the specific inhibition or activation
of, potentially, any G protein of interest. The key feature is
the introduction of a subtle but unique structural distinc-
tion between the nucleotide-binding site of a chosen G
protein and those of all other G proteins. This distinction
was accomplished by introducing a space-creating muta-
tion in the active site of the G protein. Using H-Ras as
a model system, we show that the mutant protein remains
fully functional, as it not only binds to its natural ligands
GDP and GTP, but also retains the ability to undergo
conformational changes in order to bind downstream
effectors exactly like the wild-type (WT) enzyme. To com-
plement this pocket, a panel of GDP and GTP analogs
bearing various bulky groups at C(7) was synthesized.
Two specifically designed orthogonal GDP and GTP ana-
logs that uniquely bind to the engineered G protein and
allow precise ‘‘on’’ and ‘‘off’’ control over its activity
were identified. Modeling studies revealed the specific
interactions responsible for the affinity and selectivity of
these orthogonal molecules for the mutant protein. This
precise control over G protein activity further led to the
selective and efficient enrichment of H-Ras effectors
from whole-cell lysate. Data obtained by using this
approach lead us to propose Nol1, a protein whose over-
expression in a variety of tumors correlates with poor
prognosis, as a putative novel effector of H-Ras. Impor-
tantly, we show that the specific interactions engineered
for H-Ras can be transferred to other G proteins in1008 Chemistry & Biology 14, 1007–1018, September 2007 ª20a straightforward manner, with the compounds designed
in this study tightly controlling their activities. As the resi-
dues mutated are highly conserved across the G protein
superfamily, three-dimensional structural information is
not required, and this approach should thus be widely
applicable.
RESULTS
Enzyme and Small-Molecule Design
Sequence alignments and structural studies have
revealed the close similarity in the nucleotide-binding
pockets of different G proteins [22]. This suggested the
feasibility of designing an orthogonal small-molecule/
enzyme system transposable to other members of this
superfamily. Drawing from our experience with kinase
engineering, we identified the much tighter (105-fold)
affinity of guanine nucleotides for G proteins compared
with that of ATP for kinases as the main technical hurdle.
We chose H-Ras as our model system since earlier
studies have illustrated both GDP- and GTP-binding
modes (Figure 1B) [2]. To design such a system, multiple
criteria had to be satisfied. For the mutant protein these
criteria were as follows: (1) an additional binding pocket
had to be created in the active site, (2) the ability to bind
GDP and GTP had to be conserved, (3) the ability to
bind its upstream and downstream effectors had to be
preserved, (4) it had to be functionally indistinguishable
from its WT counterpart in cells, and (5) the mutations
had to be in a conserved locus so that they could be trans-
lated to other G proteins. Orthogonal small molecules had07 Elsevier Ltd All rights reserved
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(A) Sequence alignment of the areas of diverse
G proteins in close contact with the guanine
ring system. Conserved residues are high-
lighted in bold, while L19, N116, and T144,
residues discussed in this study, are italicized.
(B) Schematic representation of GDP binding
to H-Ras WT. Amino acid side chains dis-
cussed in the text are numbered.
(C) Representation of H-Ras 19A-116A bound
to GDP. The hydrophobic pocket created by
combinations of L19 and N116 mutations to
alanine or glycine has approximate dimensions
of 10 A˚ in length and 3–6 A˚ at the entrance,
depending on the combination of mutations.several requirements to satisfy as well: (1) they had to
possess greater affinity than GDP and GTP for the mutant
protein to be able to compete with them in a cellular envi-
ronment, (2) they could not bind to the WT G protein, even
at high concentrations, and (3) their binding had to have
a defined effect on the mutant enzyme by turning it selec-
tively into the ‘‘on’’ or ‘‘off’’ conformation.
Accordingly, we conducted initial modeling studies for
the rational design of mutant H-Ras proteins possessing
an additional binding pocket in the active site and of small
molecules complementing this additional pocket. The
residues considered for mutagenesis had to be located
near the guanine ring system but be far removed from
the switch I and II areas that surround the GTP g phos-
phate. These criteria suggested the mutation of L19,
N116, or both. Importantly, these residues are highly con-
served in other family members (Figure 2A) [23]. All of the
members of small G protein (159 members) and heterotri-
meric G protein superfamilies (16 members) lack alanine
or glycine at these two positions (L19, N116) [24]. While
the function of L19 has not been studied previously,
N116 is believed to help stabilize the nucleotide-binding
pocket [25]. Since they are on the backside of this binding
site, they are away from the regions involved in conforma-
tional changes and effector binding, and their replacement
was likely to have minimal impact on H-Ras function.
Furthermore, we noticed the presence beyond them of
a pocket lined with hydrophobic residues (Figure 2B).
We postulated that the combined mutation of these two
residues to either glycine or alanine would produce
mutants possessing hydrophobic cavities of various sizes
and shapes (Figure 2C). Importantly, D119, a key residue
selecting for GTP over ATP and other nucleotides by
hydrogen bonding to both the N(1) nitrogen and the C(2)
exocyclic amine, was left untouched by this design.
To complement these mutations, we envisioned that
molecules bearing bulky lipophilic moieties attached to
GDP or GTP scaffolds might be able to target the newlyChemistry & Biology 14, 1007–101created hydrophobic pocket. Using GDP and GTP as
our compound scaffolds ensured that the orthogonal
small molecules would probably use similar binding
modes and therefore inactivate or activate the mutant
enzyme, respectively. Furthermore, having the natural
substrates as our chemical templates increased the likeli-
hood of producing compounds with a similar affinity as
a starting point. The incorporation of bulky substituents
was expected to help fulfill two important criteria. First,
these large groups would ensure very selective binding
to the mutant enzyme since severe steric clashes would
occur with the WT enzyme. Second, the additional hydro-
phobic interactions secured by the insertion of these
groups in the hydrophobic pocket were predicted to
selectively increase the affinity of the analogs, but not
that of GDP/GTP, for the mutant protein. Accordingly,
substitutions were made at either the C(6) or N(7) position
of the guanine ring system; these substituents face the
newly introduced cavity (Figure 2C). For the second class
of compounds, the N(7) nitrogen atom had to be
exchanged for a carbon atom since its derivatization
would have led to either the absence of an unsaturated
bond between atoms N(7) and C(8) or the presence of
a positively charged N(7) quaternary ammonium moiety.
The latter modification was already shown to be deleteri-
ous for nucleotide binding in previous studies [26].
Furthermore, because the entrance of the pocket was
calculated to be rather narrow and because we wanted
to allow some degree of conformational freedom for
proper binding, we wished to introduce a flexible linker
unit between the guanine ring and the hydrophobic head
(Figure 2C).
Inhibitor Synthesis
Introduction of the carbon atom at position 7 was achieved
by using C(7)-deazaguanine (1), prepared according to
published procedures, as the starting material[27]. Briefly,
C(7)-deazaguanine (1) was functionalized to permit8, September 2007 ª2007 Elsevier Ltd All rights reserved 1009
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(A) Conditions: (i) POCl3,N,N-dimethylaniline, reflux, 3 hr, 79%; (ii) PivCl, pyridine, 1 hr, 62%; (iii)N-iodosuccinimide, THF, 1 hr, 86%; (iv) 3, KOH, TDA,
MeCN, 24 hr, 18%; (v) NaOH, dioxane, reflux, 4 hr, 71%; (vi) RChCH, Pd(PPh3)4, CuI, TEA, DMF, 4 hr, 72%–98%; (vii) H2, Pd/C, 1–8 hr, 44%–97%;
(viii) 70% aq.TFA, 1 hr, 65%–96%; (ix) POCl3, trimethylphosphate, 0
C, 2 hr; (x) CDI, DMF, 24 hr; (xi) phosphoric acid, nBu3N, MeOH-DMF, 7%–72%
(over three steps); (xii) POCl3, trimethylphosphate, 0
C, 2 hr; (xiii) CDI, DMF, 24 hr; (xiv) pyrophosphoric acid, nBu3N, MeOH-DMF, 33% (over three
steps).
(B) Comparison of the inhibition of [g-32P]GTP binding to H-Ras WT and AA enzymes by compounds 7a–7g and 8 at 100 mM. The ability of [g-32P]GTP
to displace inhibitors bound to the enzymes was measured by a filter binding assay. The enzymes were loaded with GDP, compounds 7a–7g and 8, or
water (Cont.) as indicated. The background binding was determined in the absence of enzyme (Bckd).
(C) Comparison of the binding affinities of GDP and 7d for H-Ras AA.regioselective C(7) monoiodination to give compound 2
and thereby activate the C(7) position for further derivatiza-
tion (Figure 3A). Additionally, the substitution pattern of 2
rendered it suitable for a stereoselective ribosylation at
N(9) with activated sugar derivative 3, made in situ with
an Appel chlorination [28]. After a one-pot hydrolysis of
the C(6) chloro, pivaloyl, and TBDMS moieties, acetonide-
protected C(7)-deazaguanosine 4 was obtained. Subse-
quent Sonogashira Pd-mediated couplings with a variety
of terminal alkynes afforded derivatives 5a–5g [29]. Impor-
tantly, regio- and chemoselective reduction of the alkyne
moiety could be achieved and was followed by deprotec-
tion of the C(20) and C(30) hydroxyls to yield compounds
6a–6g. Finally, the C(50) introduction of the two phosphate
groups was done sequentially to afford GDP analogs
7a–7g [17]. Triphosphate derivative 8 was prepared in a
similar fashion by coupling first a single phosphate and
then a pyrophosphate moiety to C(7)-deazaguanosine 6d.1010 Chemistry & Biology 14, 1007–1018, September 2007 ª20Nucleotide-Binding Specificities of WT
and Mutant H-Ras
In order to create a variety of novel hydrophobic pockets,
amino acids L19 and N116 were mutated to either alanine
or glycine in all possible combinations. Overall, eight
mutant H-Ras proteins were expressed as GST fusion
proteins in Escherichia coli (19G-116N, 19A-116N, 19L-
116G, 19L-116A, 19A-116A, 19G-116G, 19G-116A, and
19A-116G). The library of analogs was screened against
both WT and mutant H-Ras enzymes by using a filter
binding assay measuring the competitive displacement
of the compounds by radiolabeled GTP [30]. Compounds
possessing a substituted amine attached to C(6) or bear-
ing large substituents at this position were unable to
bind to the mutant proteins (data not shown). While com-
pounds bearing an oxygen atom at C(6) and smaller sub-
stituents could inhibit some of the mutant enzymes, they
also bound to H-Ras WT, and this lack of selectivity07 Elsevier Ltd All rights reserved
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Ras 19A-116A (H-Ras AA) displayed the most promising
results of all mutant enzymes for the C(7)-deazaguanine
series of inhibitors (Figure 3B). While compounds 7a–7g
did not inhibit H-Ras WT, derivatives 7d and 7e
efficiently prevented nucleotide exchange in H-Ras AA.
Clear structure-activity relationships were apparent from
these results. First, an unsaturated (planar) hydrophobic
head was required for binding, as 7a–7c were inactive.
Second, the two-methylene linker unit was found to be
necessary, as 7f did not bind to the enzyme. Finally, mod-
ifications on the aromatic ring revealed that a small para
substitution (7e) could be tolerated, while fusing another
ring was not (7g). After confirming the binding selectivity
of 7d, its affinity was then compared to that of GDP
(Figure 3C). Interestingly, 7d was less easily displaced
by [g-32P]GTP than GDP itself, exhibiting 5-fold greater
affinity for the mutant enzyme. This result indicated that
the most demanding criterion, potency of the compounds
versus the endogenous substrates, had been satisfied.
Tight binding of several GDP derivatives to H-Ras AA
appeared to confirm that their binding mode was likely
similar to that of GDP itself. Accordingly, this possibility
strengthened our original prediction that the triphosphate
equivalent of 7d, compound 8, might be a specific activa-
tor of H-Ras AA. After its synthesis, 8 was tested for its
ability to prevent GTP binding to both H-Ras WT and
H-Ras AA (Figure 3B). Specific binding of 8 to H-Ras AA
was observed (Figure 3B), further implying that the binding
mode of compounds 7d and 8 might be analogous to that
of GDP and GTP, respectively.
Characterization of Orthogonal Pairs
H-Ras AA-7d and H-Ras AA-8
Once the selectivity and potency of 7d and 8 were deter-
mined, we then investigated the ability of H-Ras AA to
induce signaling in vitro and in a cellular context. Previous
reports have documented the use of the GST-tagged Ras-
binding domain (RBD) of Raf1 kinase in selectively pulling
down GTP-loaded Ras to quantify Ras activation [31, 32].
We used this experimental setup to verify whether the
engineered protein would still function properly as
a ‘‘switch.’’ H-Ras WT and H-Ras AA were loaded with
GDP, GTP, 7d, or 8 and incubated with GST-RBD
attached to glutathione Sepharose beads. The unbound
H-Ras was removed during the washing steps, allowing
for the quantitation of protein bound (active Ras) to RBD
by anti-Ras immunoblotting. As expected, minimal protein
was observed for GDP-loaded, compared to GTP-loaded,
H-Ras WT (Figure 4A, lane 1 versus lane 2) [32]. A similar
pattern was visible for H-Ras AA (lane 3 versus lane 4).
Furthermore, the inactivating effect of 7d binding was
illustrated by the low amount of mutant protein observed
binding to RBD (lane 5). Interestingly, H-Ras AA loaded
with triphosphate derivative 8 bound to RBD as well as
when GTP was employed (lane 6 versus lane 4), thus
indicating that 8 cannot only selectively bind to but also
activate the mutant enzyme. H-Ras WT did not show
any binding with either 7d or 8, as expected (Figure 4B).Chemistry & Biology 14, 1007–101Overall, these results demonstrate that the engineered
H-Ras conserves the ability to bind an effector selectively
in the presence of GTP and, implicitly, to transmit signals.
More importantly, compounds 8 and 7d can turn it ‘‘on’’
and ‘‘off,’’ respectively.
While H-Ras AA was demonstrated to retain its nucleo-
tide- and effector-binding abilities in vitro, we sought both
in vitro and in vivo confirmation of the functional innocu-
ousness of the mutations chosen. This criterion for confor-
mation was that the mutant protein should not only bind
the same effectors, but also respond to the ‘‘on/off’’
switch mechanism as precisely as the WT enzyme. First,
we investigated the interactions of H-Ras with the macro-
molecules that directly regulate its activity: a GEF (cdc25)
and a GAP (RasGAP). The rate of background nucleotide
exchange is identical for both H-Ras WT and H-Ras AA
(Figure 4C). More importantly, the presence of cdc25
enhances the exchange rate to the same extent in each
case (Figure 4C). Similar results were observed when
GTP hydrolysis rates were analyzed in the presence and
absence of RasGAP (Figure 4D). Based on these experi-
ments, it can be concluded that the mutations introduced
did not affect the interaction of H-Ras with the proteins
regulating its activation status. Since H-Ras is known to
induce transformation when overexpressed in NIH 3T3
fibroblasts [33], we established clonal cell lines expressing
either H-Ras WT or H-Ras AA to compare their pheno-
types. H-Ras AA-expressing NIH 3T3 cells were indistin-
guishable from the H-Ras WT-expressing cells, when
Ras was present in comparable amounts (Figure 4E).
Additionally, a proliferation assay was conducted to quan-
tify the transformation abilities of either protein (Figure 4F).
While few colonies were observed in the absence of any
overexpressed Ras protein in the soft agar assay, cell lines
expressing either type displayed a similar number of colo-
nies. Engineered H-Ras thus appears to retain the trans-
forming abilities of its WT counterpart, demonstrating
conservation of the functions necessary for this event
in vivo.
Since H-Ras AA behaved like the WT enzyme in
biochemical and cellular assays, we wished to further in-
vestigate its specific binding to orthogonal compounds
7d and 8. Using X-ray crystallography data [34] represent-
ing H-Ras WT bound to GDP (Figure 1B), we conducted
a molecular modeling study to scrutinize the binding of
inhibitor 7d to H-Ras AA. The tight affinities displayed by
7d and 8 and their ability to control the conformational
changes dictating association with effectors such as
Raf1 kinase strongly suggested that their binding modes
were similar to that of GDP and GTP, respectively. Inter-
estingly, a stochastic search revealed the existence of
a unique allowed conformation for the insertion of the
aromatic ring into the newly created hydrophobic pocket
(Figure 4G). The conformational freedom afforded by the
two-methylene linker is clearly necessary for the proper
localization of the ring. The additional binding affinity
resulting from these novel hydrophobic interactions offers
a reasonable explanation for the enhanced affinity of
nucleotide 7d versus GDP for the engineered enzyme.8, September 2007 ª2007 Elsevier Ltd All rights reserved 1011
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(A) Pull-down of H-Ras with GST-RBD bound to glutathione Sepharose beads. The amount of H-Ras WT (WT) or H-Ras AA (AA) pulled down by
GST-RBD in the presence of GDP (lanes 1 and 3), GTP (lanes 2 and 4), 7d (lane 5), and 8 (lane 6) is shown by anti-Ras immunobloting.
(B) Pull-down of H-Ras WT with GST-RBD bound to glutathione beads with compound 7d (lane 1), 8 (lane 2), GDP (lane 3), and GTP (lane 4).
(C) Amount of exchanged GTP as a function of time for H-Ras WT and H-Ras AA in the absence and presence of cdc25c.
(D) Amount of hydrolyzed GTP (Pi) as a function of time for H-Ras WT and H-Ras AA in the absence and presence of RasGAP.
(E) Transformation of NIH 3T3 fibroblasts by H-Ras WT and H-Ras AA. Clonal cell lines isolated from NIH 3T3 fibroblasts infected with retroviruses
containing H-Ras WT and H-Ras AA are shown. H-Ras levels are shown in the insert: (1) Control, (2) H-Ras WT, and (3) H-Ras AA.
(F) Number of colonies counted in a soft agar assay conducted with the clonal cell lines described above. The p value displayed was obtained from
a two-tailed t test.
(G) Ribbon representation of the proposed binding mode of 7d to H-Ras AA; 7d docking was conducted by using the modeling software MOE, and the
output was visualized with Insight II.Selective Identification of G Protein Effectors
Weexpanded thisapproach further to identify, ina specific,
unbiased manner, novel H-Ras effectors in complex bio-
logical samples. GST-tagged H-Ras AA molecules bound
to glutathione Sepharose beads were loaded with triphos-
phate8 for activation. Acell lysate, dialyzed against a saline
solution containing both EDTA and GDP, was then added
to the H-Ras AA beads in the presence of excess magne-
sium, a necessary cofactor for tight nucleotide binding
[22]. H-Ras AA was activated and able to bind its down-
stream effectors. As multiple members of the Ras family
can bind to the same effectors [34], this specificity of acti-
vation prevents the competition of H-Ras AA with multiple
G proteins for the same set of effectors. After washings
aimed at removing unbound proteins, the beads were1012 Chemistry & Biology 14, 1007–1018, September 2007 ª2treated with excess EDTA and GDP to loosen the binding
of 8 to H-Ras AA and to ensure its replacement by GDP
[26]. As a result, conformational changes of H-Ras AA led
to the selective release of the bound effectors under mild
conditions (Figure 5A, lane 2), while proteins binding un-
specifically to the beads were retained. The addition of
controls such as ‘‘blank’’ elution (no EDTA or GDP) of an
identical sample (lane 1) or the elution of proteins binding
to GDP-loaded H-Ras AA (lane 3) allows for the further
elimination of background signal. As a positive control,
we monitored the amount of Raf kinase, a known H-Ras
effector, present in the different elution fractions. Figure 5B
documents the presence of Raf in the specific elution frac-
tion (lane 2), while none was found in the two control sam-
ples (lanes 1 and 3). Furthermore, similar experiments007 Elsevier Ltd All rights reserved
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(A) Silver-stained gel displaying the proteins isolated from whole-cell lysate by GST-H-Ras AA activated with 8 (10 mM, samples 1 and 2) or inactivated
with GDP (10 mM, sample 3) and eluted with EDTA and GDP (lanes 2 and 3) or buffer without EDTA or GDP (lane 1) as described in Experimental
Procedures. Proteins uniquely present in lane 2 associated with activated H-Ras AA and were specifically released after H-Ras AA inactivation
and are therefore candidate effectors of H-Ras.
(B) Anti-Raf1 immunoblot of the same experiment displaying Raf protein eluted from samples 1–3.
(C) Silver-stained gel displaying the proteins isolated from whole-cell lysate by GST-H-Ras AA activated with 8 (10 mM, samples 1 and 2) or with GTP
(10 mM, samples 3 and 4) and eluted with EDTA and GDP (lanes 2 and 4) or buffer without EDTA or GDP (lane 1 and 3) as described in Experimental
Procedures.
(D) GST-H-Ras activated with GTP (10 mM) and eluted with buffer only (lane 1) or with buffer supplemented with EDTA and GDP (lane 2).
(E) Sequence alignment of human Nol1 (accession number P46087, amino acids 425–535) with the RA domain of human Ral-GDS (accession number
Q12967, amino acids 798–883). Alignment was produced by using ClustalW and was manually refined and colored by using Seaview (red, negatively
charged; blue, positively charged; green, aromatic; yellow, lipophilic amino acids). Arrows indicate amino acids important in the binding of RalGDS to
H-Ras.
(F) Nol1 immune complexes incubated with no protein, Ras-GTP, or Ras-GDP were immunoblotted for Nol1 and Ras.
(G) GST-Ras on glutathione beads loaded with GDP (lane 1) or GTP (lane 2) were incubated with MCF7 cell lysates as described in Experimental
Procedures. Nol1 IB shows specific binding upon Ras activation (lane 2).comparing GTP with compound 8 led to higher levels of
isolated proteins with the latter (Figure 5C, compare lanes
2 and 4). Presumably, this effect may stem from the fact
that all G proteins should be activated by GTP. Similar re-
sults were obtained when WT Ras was used with GTP,
showing minimal effectors (Figure 5D). The protocol devel-
oped thus permits the specific isolation and identification
of novel effectors of G proteins on a proteome-wide scale.
Two-dimensional gel electrophoresis can then be used for
the resolution of individual proteins and mass spectrome-Chemistry & Biology 14, 1007–1018try for their identification. An important feature of this
method is the large enrichment in effector proteins due to
the specific binding and elution procedures with a mild
EDTA-mediated release mechanism that favors elution of
the proteins specifically bound to activated H-Ras.
Proposal of Nol1 as a Putative Novel
Effector of Ras
Using the approach outlined above, Nol1 (proliferating cell
nucleolar protein p120) was suggested as a putative, September 2007 ª2007 Elsevier Ltd All rights reserved 1013
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consensus sequences have been identified for Ras effec-
tors to date—RBD and RA (Ras association) domain—al-
though not all proteins bearing RA domains identified
through sequence alignments are genuine Ras effectors
[35]. No RBD or RA domains are predicted to exist in
Nol1 according to the SMART and PFAM databases [36,
37]. Interestingly, while the alignment of Nol1 with the
RBD of Raf was unsuccessful, significant overlap (17%
identity) was observed with the RA domain of RalGDS
(Figure 5E), another well-characterized effector of Ras.
Furthermore, a number of the amino acids depicted as im-
portant in the binding of RalGDS to Ras appear to be pre-
served [35, 38].
To confirm that Nol1 can bind to H-Ras, Nol1 immune
complexes were isolated from MCF7 cells and incubated
with H-Ras WT preloaded with either GTP or GDP. Nol1
specifically bound to the active form (lane 2), but not to
the inactive form (lane 3), of Ras (Figure 5F). Additionally,
GST-Ras (on beads) preloaded with either GTP or GDP
Figure 6. System Transfer to Other G Proteins
(A) Close-up view of 7d inside the modified active site; important amino
acids are depicted.
(B) Comparison of the inhibition of [g-32P]GTP binding to Rap1B WT
and AA enzymes by compounds 7d and 8 at 100 mM. The ability of
[g-32P]GTP to displace inhibitors bound to the enzymes was measured
by a filter binding assay. The enzymes were loaded with GDP,
compounds 7d and 8, or water (Cont.) as indicated. The background
binding was determined in the absence of enzyme (Bckd).1014 Chemistry & Biology 14, 1007–1018, September 2007 ª2was added to MCF7 cell lysates, and Nol1 binding was
probed. Nol1 binds to active Ras specifically (Figure 5G).
This result suggests that Nol1 may be a novel effector of
H-Ras.
System Transfer to Other G Proteins
In the design phase of this study, great emphasis was
placed on the potential transferability of the designed
orthogonal small-molecule/protein pairs to other G pro-
teins. The overall fold of the guanine nucleotide-binding
domain of G proteins has been studied previously and
was found to be conserved across all subfamilies, result-
ing in substantial amino acid identity in residues located
near the active site [22]. Investigation of the engineered
hydrophobic pocket highlighted the pivotal role of threo-
nine 144 (T144) in allowing for the presence of the phenyl
ring inside the pocket (Figure 6A). As the aromatic ring
nestles between L19A and N116A, this is the closest non-
conserved amino acid. Its identity can thus be potentially
crucial in allowing or disrupting the binding of compounds
7d and 8 to a given engineered G protein. Due to the con-
served hydrogen bond between the amide nitrogen of
A146 and O(6), the orientation of T144 inside the pocket
is well preserved in G proteins. Interestingly, sequence
alignments reveal that this position is occupied in the
vast majority of cases by similar amino acids such as
cysteine or serine (Figure 2A).
Rap1 proteins are implicated in growth and differ-
entiation modulation, secretion, cell adhesion, and mor-
phogenesis [34]. Sequence alignments indicated the
conservation of L19 and N116, and thus these residues
were targeted for alanine mutations. Importantly, the other
key residue, T144 in H-Ras, corresponds to S146 (Fig-
ure 2). Rap1B thus provided an opportunity to test our
compounds with a different amino acid at this position
and validate the strategy used for creating inhibitor 7d
and activator 8, which are specific for the G protein family.
A binding assay with both Rap1B WT and Rap1B AA in
conjunction with GDP, 7d, or 8 was then carried out. Re-
sults displayed the selective binding of derivatives 7d
and 8 to the engineered Rap1B enzyme only (Figure 6B),
further illustrating the potential for straightforward adapta-
tion of the orthogonal small-molecule/G protein pairs
crafted in this study to any G protein of interest.
DISCUSSION
The importance of Ras proteins as crucial players at the
crossroads in cellular signaling pathways is well estab-
lished [7]. However, the overall framework of Ras interac-
tions is far from complete, and the collection of Ras
effectors continues to expand, uncovering links between
Ras and other cellular signaling pathways. Ras is emerg-
ing as a dual regulator of cellular functions, playing either
positive or negative roles in the regulation of proliferation
and apoptosis [38]. Characteristics of G proteins, such
as picomolar binding affinities for GDP and GTP, have pre-
cluded the development or the isolation of active-site-
directed inhibitors or activators. To answer this need, we007 Elsevier Ltd All rights reserved
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tion of H-Ras activity that could then easily be applied to
other G proteins. This tool could thus be used for decipher-
ing individual G protein signaling cascades through the
tight ‘‘on’’ and ‘‘off’’ control afforded by small molecules
and the specific isolation of G protein-binding partners.
To accomplish this, an additional binding pocket was engi-
neered into the guanine nucleotide-binding site (Figure 2),
and GDP/GTP derivatives bearing bulky substituents were
synthesized to complement these mutations (Figure 3A).
Compound 7d was observed to bind selectively and po-
tently to H-Ras AA, resulting in the inhibition of its activity
(Figures 3B, 3C, and 4A). In contrast, triphosphate analog
8 specifically activated H-Ras AA, as observed by using
the RBD pull-down (Figures 4A and 4B). Conservation of
the functions of the engineered H-Ras was first demon-
strated by its preserved ability to bind GDP and GTP (Fig-
ures 3B and 3C). Second, GDP and GTP were confirmed to
induce conformational changes in the engineered protein
similar to those produced in the WT enzyme (Figure 4A).
Third, neither GEF-mediated nucleotide exchange nor
GAP-stimulated GTP hydrolysis were found to be affected
in the engineered protein (Figures 4C and 4D). Additionally,
while most previously known H-Ras mutants, including
xanthosine nucleotide-binding proteins, display either
dominant-negative or constitutive activity properties in a
cellular context [21], H-Ras AA behaved as its WT counter-
part in NIH 3T3 fibroblasts (Figures 4E and 4F). Finally, we
conducted modeling studies illustrating the potential for
transfer of the system created, as the orthogonal inhibitor
(7d) and activator (8) appeared to have the same binding
mode as their natural counterparts (Figure 4G).
Importantly, since engineered H-Ras is functionally
indistinguishable from H-Ras WT, this approach can be
utilized for in vivo studies in different cell types. While
nucleotide analogs are not cell permeable, whole-cell dial-
ysis, microinjection, and cell permeabilization are effective
techniques for small-molecule-based activation or inhibi-
tion to study cellular events. We reported recently the
successful use of an ADP analog to delineate the role of
myosin-1c in hair-cell adaptation in vivo [16]. Moreover,
this chemical-genetic strategy is especially powerful, as
it allows for negative controls not accessible by other
methods, such as using H-Ras WT-expressing cells for
filtering out the nonspecific effects of microinjection and
other artifacts. These tools, in conjunction with the highly
specific inhibition or activation of a desired G protein in the
cell should thus enable us to study the role of G proteins
implicated in cytoskeleton dynamics, cell-cycle progres-
sion, and nuclear transport, for example.
The diversity of Ras-mediated effects may be related, in
part, to differential involvement of Ras homologs in dis-
tinct cellular processes [7]. Therefore, the identification
of the specific effectors of Ras homologs in different cell
types will significantly enrich our understanding of their
individual functions [39]. To this aim, we utilized this chem-
ical-genetic tool to uncover novel H-Ras effectors in
whole-cell lysate. Through the selective activation of H-
Ras AA by 8 and the specific EDTA- and GDP-mediatedChemistry & Biology 14, 1007–1018release, H-Ras effectors could be highly enriched in the
final elution (Figures 5A and 5C). This approach offers
a novel way to study any G protein through the identifica-
tion of its binding partners.
We demonstrate the feasibility of this approach by iden-
tifying and proposing Nol1 as a putative novel effector of
H-Ras (Figures 5E–5G). Hypothesized to be an RNA meth-
yltransferase, Nol1 is expressed by cells in early G1 phase
and peaks during S phase [40]. Multiple reports document
its overexpression in a variety of tumors, including lung
adenocarcinoma [41], prostate adenocarcinoma [42],
breast cancer [43], oral carcinoma [44], follicular lym-
phoma [45], and human gliomas [46], and this overexpres-
sion is correlated with poor prognosis and shorter patient
survival. Its expression levels in a wide range of human
cancer cell lines were also found to be predictive of cellu-
lar doubling times [47]. Furthermore, expression of Nol1 in
NIH 3T3 cells results in transformation and produces rap-
idly growing tumors in nude mice [48]. Identification of
Nol1 as a possible downstream effector of Ras might
thus suggest a novel mechanism by which Ras may influ-
ence carcinogenesis. Further research will be necessary
to investigate the consequences of activated H-Ras bind-
ing to Nol1 in healthy or diseased tissue.
Finally, to ensure the transferability of this approach to
other G proteins of interest, we demonstrated a straight-
forward transfer to Rap1B (Figure 6B). As understanding
the precise functions of closely related family members
is a current frontier in Ras research, this specific control
over the activity of a given member is of particular interest
[7]. More importantly, successful sensitization of a different
G protein to the compounds controlling the activity of the
previously engineered H-Ras demonstrates the potential
breadth of application of this approach.
SIGNIFICANCE
In conclusion, we demonstrate the structure-based
design of complementary small-molecule/protein
pairs for H-Ras. The strategy employed allows for
the selective inhibition and activation of an engineered
H-Ras mutant by two related compounds. The high
degree of homology between nucleotide-binding sites
and the conservation of the residues targeted for
mutation suggests that other members of the family
can be successfully sensitized to the action of modu-
lators 7d and 8. Indeed, the approach was generalized
to an additional G protein, Rap1B. Its application fur-
ther led to the proposal of Nol1 as a putative novel
H-Ras effector. Due to its absolute selectivity, this
chemical-genetic approach should be a valuable addi-
tion to researchers’ toolkits for the functional study of
individual members of the G protein family.
EXPERIMENTAL PROCEDURES
Cloning and Expression of H-Ras and Rap1B Mutants
The mutant human H-Ras protein constructs were created in the
pGEX-4T1 vector by using the QuikChange protocol (Stratagene). A, September 2007 ª2007 Elsevier Ltd All rights reserved 1015
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50 mg/ml carbenicillin and was grown at 37C overnight. This culture
was added to 500 ml LB superbroth. After it had grown to an OD of
0.6, protein synthesis was induced by IPTG (50 mM) and by further
shaking at 30C for 12 hr. After centrifugation at 3,500 3 g for
15 min at 4C, the cell pellet was frozen at 80C for 1 hr. The pellet
was resuspended in chilled lysis buffer (20 mM HEPES [pH 7.5],
75 mM KCl, 25 mM MgCl2, 5 mM DTT, 0.1 mM EDTA, 0.05% Triton
X-100, and protease inhibitors [Sigma]) and was further sonicated for
60 s. The resulting lysate was centrifuged at 30,000 3 g for 30 min at
4C, and the supernatant was added to glutathione Sepharose beads
and was incubated at 4C with rotation. The beads were washed
with lysis buffer once, then with wash buffer (50 mM Tris-HCl [pH
7.5], 50 mM NaCl, 1 mM DTT) three times. The protein was eluted
with 10 mM glutathione in wash buffer, concentrated, and dialyzed
overnight against storage buffer (50 mM Tris-HCl [pH 7.5], 50 mM
NaCl, 0.2 mM DTT, 0.1 mM EDTA). Protein concentration was deter-
mined by a Bradford assay, and the protein purity was assessed by
gel electrophoresis.
Guanine Nucleotide Exchange Assays
The purified proteins (inhibitor screening: 5 mg; affinity curve: 300 ng)
were incubated in 40 ml of GTP exchange buffer (50 mM Tris-HCl [pH
7.5], 50 mM NaCl, 0.5 mM MgCl2, 1 mM DTT, 1 mg/ml BSA) containing
either water, GDP (100 mM) or an inhibitor (100 mM) for 30 min at 25C.
This preincubation was followed by the addition of GTP (10 nM) con-
taining 2 mCi [g-32P]GTP (NEN) with 25 mM MgCl2. After another
5 min of incubation, the reaction mixture was applied to a nitrocellulose
filter (Millipore) prewetted with wash buffer (50 mM Tris-HCl [pH 7.5],
10 mM MgCl2), and the filter was then washed with 10 ml wash buffer.
Filters were dried, and the bound radioactivity was measured by scin-
tillation counting.
RBD Pull-Down Assay
The purified proteins (150 ng) were incubated in 1 ml of loading buffer
(100 mM Tris-HCl [pH 7.5], 2 mM EDTA, 1 mM DTT, 1 mg/ml BSA) in
the presence of 10 mM GDP, GTP, 7d, or 8 for 15 min at 25C for load-
ing the proteins with the appropriate nucleotides. After loading, MgCl2
(20 mM) was added along with GST-RBD (1.2 mg), comprising Raf
kinase amino acids 53–131, bound to glutathione Sepharose beads.
The resulting suspensions were incubated with rotation for 15 min at
4C. The beads were then washed three times with 1 ml washing buffer
(50 mM Tris-HCl [pH 7.5], 100 mM NaCl, 20 mM MgCl2, 1 mM DTT) and
boiled in SDS loading buffer, and the samples were separated by elec-
trophoresis. After transfer, the PVDF membrane was probed with anti-
H-Ras (Santa Cruz, C-20), and the amount of H-Ras bound to the RBD
glutathione Sepharose beads was visualized by using anti-rabbit HRP
in conjunction with West Pico (Pierce).
Nol-1 Pull-Down Assay
Nol-1 immune complexes (Protein Tech Group, Chicago) isolated from
MCF7 cells were incubated with GST-Ras (1 mg each) preloaded with
either GTP or GDP as described above. The resulting suspensions
were incubated with rotation for 20 min at 4C. The beads were then
washed three times with 1 ml of washing buffer as described above,
boiled in SDS loading buffer, and separated by electrophoresis. After
transfer, the PVDF membrane was probed with anti-H-Ras and anti-
Nol1 (for loading control), followed by anti-rabbit HRP in conjunction
with West Pico (Pierce).
Alternatively, GST-Ras on glutathione beads (1 mg each) preloaded
with either GTP or GDP was incubated with MCF7 cell lysates with ro-
tation for 20 min at 4C in the presence of GTP or GDP (10 mM). The
beads were washed, boiled, separated, and transferred as described
above. The PVDF membrane was probed with anti-Nol1 and anti-Ras
(for loading control).1016 Chemistry & Biology 14, 1007–1018, September 2007 ª2GAP-Mediated Nucleotide Hydrolysis Assay
A total of 5 mg of either H-Ras or H-Ras AA protein was incubated with
5 mM GTP and 2 mCi [g-32P]GTP in GTPase reaction buffer at 30C
(20 mM Tris-HCl [pH 7.5], 100 mM NaCl, 1 mM DTT) in triplicate in a to-
tal assay volume of 350 ml. After 10 min, MgCl2 was added at a final
concentration of 25 mM. Samples (50 ml) were collected at different
times (starting from t = 0–60 min), and the reaction was stopped by
adding 750 ml 5% w/v activated charcoal in 20 mM ice-cold phospho-
ric acid and centrifuging for 10 min. Radioactivity was quantified by
liquid scintillation counting of 500 ml of the supernatants containing
hydrolyzed 32Pi. For tubes containing GAP, 5 mg of GST-GAP was
added after the preloading step, and samples were collected at
2 min intervals up to 10 min.
GEF-Mediated Nucleotide Exchange Assay
A total of 5 mg of either H-Ras or H-Ras AA was preloaded with 1 mM
GTP and 5 mCi [a-32P]GTP in loading buffer in triplicate (20 mM Tris
[pH 7.5], 100 mM NaCl, 1 mM DTT) at 30C in a total volume of
350 ml. After 40 min, GTP was added at a final concentration of
100 mM loading buffer (50 ml). Samples (50 ml) were collected and
added to 1 ml ice-cold stop buffer (50 mM Tris-HCl [pH 7.5], 20 mM
MgCl2, 1 mM DTT, 10 mg/ml BSA) at regular intervals (starting at t = 0
up to 60 min). The resulting mixture was filtered through prewetted
nitrocellulose filters (0.45 mm, white grided HAWG, 25 mm) under
vacuum and washed with 10 ml wash buffer (50 mM Tris-HCl
[pH 7.5], 10 mM MgCl2). Radioactivity was quantified by liquid scintil-
lation counting after drying the filters. For tubes containing GEF, 1 mg
cdc25c was included in the reaction mixture after the preloading
step, and samples were collected at 2 min intervals up to 10 min.
Transforming Abilities of H-Ras WT and H-Ras AA
NIH 3T3 cells were cultured in DMEM supplemented with 10% bovine
calf serum. H-RasWT andH-Ras AA were cloned into pBabe puro and
transfected into Bosc23 cells to produce virus. Pools of transduced
rodent fibroblasts were selected by addition of puromycin (2.5 mg/ml).
Clonal cells were isolated and grown under selection for 2 weeks. Cells
displaying similar amounts of H-Ras WT and H-Ras AA by anti-H-Ras
immunoblotting were chosen for further studies.
Soft-Agar Colony Formation Assay
Wild-type and H-Ras AA-expressing NIH 3T3 cells and pBabe vector-
infected NIH 3T3 cells were plated in DMEM (103, 104, and 105 cells per
dish, each in triplicate), 0.3% agar, and 10% calf serum in 353 10 mm
dishes. Transformed colonies were counted after 3 weeks.
Molecular Modeling
Using PDB entry 1Q21 as a template, docking of 7d to H-Ras AA was
accomplished by using MOE (Chemical Computing Group). Briefly,
amino acids L19 and N116 were mutated to alanine residues. The
resulting structure (bound to GDP) was then energy minimized. After
modifying GDP into 7d, all atoms of the protein/nucleotide complex
were fixed, except for those that were part of the added 1-ethylphenyl
unit. A stochastic conformational search was run for these atoms, and
a unique favorable conformation was obtained. This confirmation was
further energy minimized, and the output was visualized with Insight II
(Accelrys).
Selective Isolation of H-Ras Effectors
The HeLa cell pellet obtained from 15 3 150 mm plates was lysed us-
ing 10 mM Tris (pH 7.5), 150 mM NaCl, 1% NP40, 2 mM EDTA, GDP
100 mM, protease inhibitors (Sigma), and phosphatase inhibitors
(Sigma cocktail I). After its centrifugation, the lysate (4.5 ml) was dia-
lyzed against 10 mM Tris (pH 7.5), 50 mM NaCl, 0.1 mM EDTA for
4 hr at 4C. Cell lysis in the presence of EDTA and GDP ensured that
all cellular G proteins were loaded with GDP, while dialysis removed
excess EDTA and GDP. The lysate was then precleared with 200 ml
glutathione Sepharose beads for 30 min at 4C. Engineered H-Ras
AA (20 mg) was immobilized on glutathione Sepharose beads007 Elsevier Ltd All rights reserved
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and 2) or with GDP (150 mM, tube 3) during an incubation (15 min, 20C)
in 100 ml 10 mM Tris (pH 7.5), 50 mM NaCl, 0.1 mM EDTA. After addi-
tion of MgCl2 (10 mM) to both beads in tubes 1–3 and dialyzed lysate,
1.4 ml lysate was added to each tube, and incubation was conducted
at 4C for 15 min with a final nucleotide concentration of 10 mM in each
tube. The beads were then washed three times with 1 ml wash buffer A
(10 mM Tris [pH 7.5], 100 mM NaCl, 10 mM MgCl2, 1 mM 8) for tubes 1
and 2 or wash buffer B (10 mM Tris [pH 7.5], 100 mM NaCl, 10 mM
MgCl2, 1 mM GDP) for tube 3. The elution was then conducted at
4C for 30 min by adding 60 ml elution buffer A (10 mM Tris [pH 7.5],
30 mM NaCl, 10 mM MgCl2, 1 mM 8) to tube 1 (blank elution) or elution
buffer B (10 mM Tris [pH 7.5], 30 mM NaCl, 20 mM EDTA, 100 mM GDP)
to tubes 2 and 3. The supernatant was mixed with SDS loading buffer
and boiled, and the proteins were separated by gel electrophoresis.
The first gel was stained with silver stain to visualize the eluted
proteins, while the other gel was transferred onto a PVDF membrane.
The membrane was probed with anti-Raf1 (Santa Cruz Biotechnology,
C-12), and the amount of Raf1 kinase present in each lane was visual-
ized with anti-rabbit HRP in conjunction with West Pico (Pierce).
Supplemental Data
Supplemental Data include synthetic procedures and characterization
data for key compounds and are available at http://www.chembiol.
com/cgi/content/full/14/9/1007/DC1/.
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